| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000016274 |
| Receipt No. | R000018884 |
| Official scientific title of the study | effectiveness of prophylaxis of post-ercp pancreatitis by a rectal diclofenac and sublingual nitrate.-randomized controlled multicenter trial- |
| Date of disclosure of the study information | 2015/02/05 |
| Last modified on | 2018/07/04 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | effectiveness of prophylaxis of post-ercp pancreatitis by a rectal diclofenac and sublingual nitrate.-randomized controlled multicenter trial- | |
| Title of the study (Brief title) | a randomized trial of rectal diclofenac and sublingual nitrate for prevention of post ercp pancreatitis | |
| Region |
|
|
| Condition | ||
| Condition | Post-ERCP pancretitis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We aimed to evaluate the effi cacy
of rectally administered diclofenac plus sublingual nitrate compared with diclofenac alone to prevent post-ERCP panceatitis. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Incidence rate of post-ERCP pancreatitis |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | patients received a 5mg
of sublingual nitrate before ERCP and received a suppository containing 50mg of diclofenac after ERCP. |
|
| Interventions/Control_2 | patients received a suppository containing 50mg of diclofenac after ERCP. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who are planned ERCP | |||
| Key exclusion criteria | 1)Patients with performance status 4.
2)Age<20 3)Body weight<50Kg 4)Patients who cannot access to Vater,s papilla. 5)Patients with a history of EST and EPBD. 6)Patients with acute pancreatitis 7)Patients with chronic pancreatitis 8)Patients with pancreatic head tumor 9)Patients who performed operation of reconstraction for intestinal track by gastrectomy. 10) Patients who had a contraindication to the use of NSAIDs and nitrate. 11) Patients who were already taking nitrates. 12)Patietns without informed concent. 13)Patients who are judged inappropriate by chief medical examiner. |
|||
| Target sample size | 900 | |||
| Research contact person | |
| Name of lead principal investigator | Hironari Kato |
| Organization | Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences |
| Division name | Department of Gastroenterology & Hepatology |
| Address | 2-5-1Shikata-cho,Kita-ku Okayama-city Okayama |
| TEL | 086-235-7219 |
| drkatocha@yahoo.co.jp | |
| Public contact | |
| Name of contact person | Takeshi Tomoda |
| Organization | Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences |
| Division name | Department of Gastroenterology & Hepatology |
| Address | 2-5-1Shikata-cho,Kita-ku Okayama-city Okayama |
| TEL | 086-235-7219 |
| Homepage URL | |
| tomotake79@yahoo.co.jp | |
| Sponsor | |
| Institute | Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018884 |